Government Will Reverse Mesothelioma Ruling

 

Government Will Reverse Mesothelioma Ruling

The Lord Chancellor, Lord Falconer has announced changes to compensation laws which will mean victims of asbestos-related cancer will receive full compensation.

(PRWEB) June 27, 2006 -- The Lord Chancellor, Lord Falconer has announced changes to compensation laws which will mean victims of asbestos-related cancer will receive full compensation. The announcement follows the House of Lords ruling in Barker v Corus in May this year that prevented thousands of mesothelioma victims from receiving a full payout. The decision reduced the amount of compensation to which they were entitled when employers and their insurers were unavailable to be sued, as well as making the whole process of claiming compensation longer and more costly. In response The Lord Chancellor, Lord Falconer and John Hutton, the Work and Pensions Secretary, will amend the Compensation Bill - currently going through Parliament - to reverse the ruling. The amendment will mean that negligent employers will be jointly and severally liable and that claimants will be able to recover full compensation from any one employer.

Peter Williams, a partner in the Asbestos Claims Department at Field Fisher Waterhouse LLP, said:
"I am delighted the government has promptly indicated their intention to restore the rights of those suffering from mesothelioma to claim full compensation from any one employer.

"Whilst we do need to look at the detail and timing of the legislation we hope to be able to tell our clients and their families we can deal with their cases speedily and that they no longer face the prospect of losing large amounts of compensation through no fault of their own."

About 1,900 people die in the UK each year from mesothelioma, a cancer of the lining of the lungs or abdomen, which is almost always caused by exposure to asbestos. Field Fisher Waterhouse LLP is one of the country’s leading asbestos disease claims firms. Over twenty-five years Rodney Nelson-Jones and his team have recovered nearly £100M in over 1,750 successful cases.

For more details or comment please contact:
Asbestos Claims Department of Field Fisher Waterhouse LLP.
Peter Williams (020 7861 4825)
Andrew Morgan (020 7861 4036)

info @ ffw.com
Field Fisher Waterhouse LLP
35 Vine Street
London
EC3N 2AA
United Kingdom
Tel 020 7861 4000
Fax 020 7488 0084

About Field Fisher Waterhouse LLP
FFW is a full service law firm based in the City of London. With 91 partners, over 180 other lawyers and over 250 support staff, we assist a wide range of domestic and international clients, with advice across a full range of commercial legal issues. Field Fisher Waterhouse LLP also houses one of the country's leading personal injury practices.

###

Press Contact: Peter Williams
Company Name: Field Fisher Waterhouse LLP
Email: email protected from spam bots
Phone: 020-7861-4825
Website: www.ffw.com

How Much Does A Prescription Drug Card Help?

 

Free Prescription Drug Card Helps with High Prescription Drug Costs in the U.S.

The Free Prescription Drug Card from www.YourRxCard.com is like a “Coupon” for Medicines. Take control of your high prescription drug costs.

(PRWEB) June 20, 2006 -- The cost of brand name prescription drugs keeps rising in the US. According the AARP, brand name prescription drugs continued to rise last year at an average rate greater than inflation. Last month, a new free prescription drug card became available to all Americans through www.YourRxCard.com to aid them in covering their prescription drug costs. In addition to instant activation, the free prescription drug card has no deductibles, waiting periods, or pre-existing exclusions.

In 2005, the AARP reports that the manufacturers’ price of brand name prescription drugs rose at an average rate of 6.0%, whereas the national inflation was only 3.4%, nearly half of the drug price increase rate. The organization’s report, which was based on a sample of 193 brand name drugs, showed that 2005 was the sixth year in a row that prescription drug manufacturers raised their prices to wholesalers and other purchasers at a rate that was disproportionate to inflation.

With prescription drug prices continually rising, and many older Americans still without insurance, the free prescription drug card offered by www.YourRxCard.com can provide them with discounted rates. The card can be used in pharmacies similarly to how a coupon is used, except that it can be re-used time and time again to help Americans cover all of their prescription drug costs.

The free prescription drug card can be obtained instantly at www.YourRxCard.com from any computer with access to a printer, and it can be used right away. High prescription drug costs no longer have to come between Americans and the medicines they need.

About www.YourRxCard.com

YourRxCard.com is a free prescription drug card program being produced to help all Americans cut their prescription drug costs. Individuals can download and print their free prescription drug card from www.YourRxCard.com, and receive savings of up to 75% at more than 50,000 national, regional, and local pharmacies. There are no deductibles, no waiting periods, and no pre-existing exclusions with the use of the card.

For more information please visit www.YourRxCard.com, or contact Rex Bowden at 866-561-1926 or via email at email protected from spam bots.

# # #

Press Contact: Rex Bowden
Company Name: YourRxCard.com
Email: email protected from spam bots
Phone: 866-561-1926
Website: www.yourrxcard.com

Pharmaceutical Company Announces New Cancer Drug

 

NeoVid Pharmaceuticals Announces Investigation of New Cancer Drug

A new cancer drug compound (dTCTinicyclic acid HCL), given the brand name Azatrol, is being investigated for a cure to cancer.

West Chester, PA (PRWEB) June 14, 2006 -- Today, Neovid Pharmaceuticals LLC (neovid.com) announced the introduction of an investigational new cancer drug, Azatrol™ (dTCTinicylic acid HCL). The company emphasizes that this drug is in the most early stages of investigation requiring extensive basic research in order to prove its theory.

This endeavor is comprised of the biosynthesis of several compounds resulting in the creation of dTCtinicylic acid HCL (which has been given the brand name Azatrol™ by NeoVid). As conceived, dTCtinicylic acid HCL will be injected into a tumor site and then It is hypothesized that malignant cells will cease to multiply, ultimately detaching from the host and subsequently becoming absorbed into the blood stream. The destroyed cells will then be safely eliminated through the patient’s own immune system.

According to John T. Jeter, President and CEO of Neovid, the company is in the process of seeking adequate funding sources to proceed with the basic research. He further reports that the fundamental science behind the investigational new compound is founded upon naturally occurring substances commonly found in phytopharmaceuticals. By subjecting these compounds to a proprietary heat process, a new molecule (dTCTinicyclic acid HCL) may be formulated.

Mr. Jeter goes on to point out that this proposed compound is highly speculative at this point and requires further investigation. To quote Mr Jeter, “The research on our investigational compound is exciting because it is a synthesis of natural plant substances. This is not as far reaching as one may think considering the fact that a powerful cancer drug Taxol® is formulated originally from the Pacific Yew Tree or Paclitaxel and another cancer drug is based the chemical navelbine found in missile-toe.”

For more information, please contact the company at http://neovid.com, by phone: 610-692-3215 or by e-mail.

###

Press Contact: John Jeter
Company Name: NEOVID PHARMACEUTICALS LLC
Email: email protected from spam bots
Phone: 610-692-3215
Website: neovid.com

Company to Create Patient Study Calendar Module for the National Cancer Institute

 

Akaza Research Partners with Northwestern and Semantic Bits, LLC to Develop Patient Study Calendar Module for the National Cancer Institute

Akaza Research has been awarded a contract by the National Cancer Institute to develop a Patient Study Calendar module for OpenClinica under the National Cancer Institute’s Cancer Bioinformatics Grid (caBIG) initiative.

Cambridge, MA (PRWEB) June 10, 2006 -- Akaza Research, the developer of OpenClinica™, the leading open source clinical research software, announced today a partnership with Northwestern University and Semantic Bits, LLC to develop software for cancer clinical trials. The group has been awarded a contract by the National Cancer Institute to develop a Patient Study Calendar platform for the National Cancer Institute’s Cancer Bioinformatics Grid (caBIG™) initiative.

The caBIG™ initiative makes critical tools and data accessible to cancer researchers worldwide to speed the development of innovative approaches for cancer prevention and treatment. The cutting-edge infrastructure developed by caBIG™ has broad utility in other disease areas as well.

The Patient Study Calendar module will be a caBIG “silver-level compliant” component that will function in harmony with other caBIG-compliant components. caBIG components are targeted for deployment in all NCI-designated cancer centers.

Key features of the Patient Study Calendar module include:

o     Patient screening and registration
o     Adaptable schedule definitions
o     Prospective forecasting of visit information
o     A framework for analyzing historical events
o     A security model suitable for multi-site protocols

The module will generate alerts for upcoming events and missed events, track and report dates of anticipated versus actual events, and report on patient accrual, missed events, and schedule deviations.

Types of research set to benefit from this module include disease prevention, therapeutic, observational, correlative, ancillary, screening, diagnostic, and biobanking studies.

About OpenClinica™

OpenClinica™ is an open source web-based software platform that enables sponsors and investigators to manage clinical research data in multi-site studies. It facilitates protocol configuration, design of case report forms, electronic data capture, and study/data management. OpenClinica™ supports HIPAA and 21 CFR Part 11 guidelines and is designed as a fully standards-based, extensible, and modular platform. OpenClinica™ v1.0 was released in October 2005 under the GNU Lesser General Public License (LGPL). See http://www.OpenClinica.org. OpenClinica 2.0 is scheduled to be released in beta this summer.

About Akaza Research

Akaza Research, a leading provider of open source clinical trial software, is headquartered in Cambridge, Massachusetts. Supported by the National Institutes of Health (NIH), Akaza has developed and commercialized OpenClinica, the leading open source clinical trial data collection and management software platform. Akaza brings Open Source Software solutions to mainstream clinical research by making high quality, standards-based systems accessible for both private and public research. Akaza Research provides support, training, and consulting services to its customers worldwide. See http://www.akazaresearch.com.

MEDIA CONTACT:     Steve Glines, sglines @ industrialmyth.com, 978-952-6340

# # #

Press Contact: Steve Glines
Company Name: Industrial Myth
Phone: 9789-952-6340
Website: http://www.akazaresearch.com/